ASCO 2024 preview – two strikes against USP1
Tango cans TNG348 while Roche’s KSQ-4279 looks virtually inactive.
Tango faces a fresh PRMT5 competitor
New clinical trial listings reveal first-in-human studies for Astra’s AZD3470, a new Car-T therapy from Caribou, a B7-H4 challenger and others.
Triple meeting 2023 – PRMT5 has a wobble
Initial data on Amgen’s AMG 193 give some Tango investors a headache.
Three mystery phase 1 entrants
Bristol, AbbVie and Jiangsu HengRui move to enter clinical trials with undisclosed mechanisms of action.
Lumakras withdrawal seems unlikely... for now
But a US adcom slams Amgen’s oversight of Codebreak-200, as the group’s KRAS rival Mirati surges on takeover talk.
Finding the USP in synthetic lethality
A flurry of activity around USP1 inhibition suggests growing interest in this novel DNA damage response mechanism.